I N T R O D U C T I O N
Atypical haemolytic uremic syndrome (aHUS) is a severe form of thrombotic microangiopathy (TMA). aHUS is considered the consequence of complement dysregulation caused by mutations in complement genes or acquired autoantibodies against complement regulatory proteins such as complement factor H (CFH) [1] . aHUS can occur at any age and, before the era of eculizumab, outcome was very poor, with up to 10% mortality in the acute phase and up to 50% of patients developing endstage renal disease [2, 3] .
In 2012, the new orphan drug, eculizumab, was approved for the treatment of aHUS. Initiation of eculizumab treatment in the acute phase of aHUS resulted in significant recovery of renal function and haematological remission of TMA occurred in almost all patients [4, 5] . According to the Summary of Product Characteristics (SPC) published by the European Medicines Agency (EMA), treatment with eculizumab consists of weekly infusions in the initial phase (up to 4 weeks) followed by eculizumab infusions every 14-21 days depending on the body weight of the patient, potentially their entire life [6] .
Currently the duration of treatment is debated. There is no strong evidence in favour of lifelong treatment. Historically, plasmatherapy (PT) was the only available treatment option, but it failed in a number of aHUS patients, leaving them dependent on dialysis. In contrast, in some patients who developed complete remission, PT could be tapered and stopped. Thus only a small proportion of aHUS patients remained on chronic PT [7, 8] . It is noteworthy that there are no studies that provide strong evidence in favour of lifelong treatment with eculizumab. This, together with the high cost of eculizumab, has stimulated a debate regarding duration of treatment. Eculizumab being one of world's most expensive drugs, the burden of lifelong treatment is substantial [4] . Patients have to return to the hospital every fortnight. Also, the long-term V C The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. 635 consequences of eculizumab treatment are unknown. The most prominent risk is the development of a severe meningococcal infection. Other adverse outcomes include the possibility of developing (neutralizing) human anti-human antibodies [5, 9] or immune-mediated drug reactions. Other side effects are not yet fully understood. For example, only recently a study was published about the potential hepatotoxicity of eculizumab [10] .
Even though the outcome of patients with aHUS has improved greatly with the implementation of eculizumab, the costs of treatment are striking. The cost-effectiveness of eculizumab, considering the price per quality-adjusted life year, is a matter of international debate. For example, one important requisite for the approved funding of eculizumab by the National Institute for Health and Care Excellence in the UK is the exploration of dose adjustment or discontinuation of eculizumab treatment [11] .
These findings underline the need for studies that evaluate optimal dosage and duration of eculizumab therapy. A growing number of case reports have emerged that suggest that eculizumab therapy can be reduced or discontinued in patients with aHUS [12] [13] [14] [15] [16] [17] [18] [19] [20] .
Eculizumab therapy became available in The Netherlands in November 2012. In view of the limited evidence for lifelong therapy, the high expenses and the yet unknown side effects of long-term eculizumab therapy, lifelong treatment of aHUS patients was considered unnecessary and undesirable. Eculizumab was tapered or stopped as early as 3 months after initiation of treatment in patients who had reached stable remission. In this retrospective study, we describe 20 patients who received eculizumab according to our local practice between 2012 and 2016.
M A T E R I A L S A N D M E T H O D S
In this descriptive study, we provide information about all paediatric and adult patients with aHUS who were treated with eculizumab from November 2012 until October 2016 at the Radboud University Medical Center (RUMC), Nijmegen, The Netherlands. Medical ethical committee approval was waived, according to Dutch law, since the study was observational and retrospective. Patients were followed regularly by one of the treating physicians (N.C.A.J.vd.K. is the treating physician for the paediatric patients and J.F.M.W. for adult patients). Patients were coded and clinical and laboratory data were analysed anonymously.
TMA was defined as signs of haemoglobin level below the lower limit of normal for the specific age together with signs indicative of haemolysis, thrombocytopenia <150 Â 10 9 /L and acute renal failure. To exclude the presence of Shiga toxinproducing Escherichia coli causing HUS (STEC-HUS) at presentation, faecal diagnostics and serological antibody assays for the O157 serotype were performed. These tests were obligatory in children and performed on indication in adult patients. The ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity was determined to exclude thrombotic thrombocytopenic purpura. Medical history was reviewed for signs of previous (suspected) aHUS episodes. Possible triggers such as drugs or malignant hypertension causing TMA and specific aHUS triggers such as pregnancy or (viral) infections were reviewed. In cases where aHUS was suspected, the presence of autoantibodies against CFH were determined in serum. Simultaneously, deoxyribonucleic acid (DNA) was collected for genetic screening of mutations in complement genes. Initially, patients were screened for mutations in CFH, complement factor B (CFB), complement factor I (CFI), complement component C3 (C3) and membrane cofactor protein (MCP/C46). In cases where no explanatory mutation was found, patients were further screened for mutations in CFH-related proteins 1-5 (CFHR1-5), diacylglycerol kinase-e (DGKE), thrombomodulin (THBD) and plasminogen (PLG). Multiplex ligation-dependent probe amplification was used to screen for possible rearrangements in the CFH/CFHR region. Hypertension was defined as the use of antihypertensives, blood pressure repeatedly measured at >140/90 mmHg in adult patients or blood pressure >95th percentile for sex, height and age in paediatric patients.
Eculizumab treatment
Eculizumab was started in adult patients with a (suspected) diagnosis of aHUS in the native kidneys who did not respond to PT or remained PT dependent. In children and in patients with recurrent aHUS after kidney transplantation, eculizumab therapy was started immediately without PT. The dose of eculizumab in the initial and maintenance phase was dependent on the body weight of the patient [6] . All patients received antibiotic prophylaxis and vaccination as appropriate. Clinical remission was defined as normalized platelet count, normalized haemoglobin level without signs of haemolysis and improved and stable kidney function.
When clinical remission was reached, eculizumab treatment was evaluated. In adult patients who received eculizumab and who had improved and stable kidney function, well-controlled blood pressure and no evidence of ongoing TMA after 3 months, eculizumab was withdrawn. In patients with aHUS after kidney transplantation or in patients who needed re-treatment because of a relapse after eculizumab withdrawal, the treatment interval was first gradually extended when clinical remission was reached. In paediatric patients, the interval was extended and patients were observed with suppressed titres of total haemolytic complement activity (CH50). However, in case of stable disease (no signs of TMA), eculizumab was gradually further extended and finally stopped. When the treatment interval was 8 weeks and no signs of TMA were present, eculizumab was stopped.
In case of therapy discontinuation, patients were closely monitored for any signs of disease recurrence. Patients were seen frequently within the first year of discontinuation for blood and urine workup, initially in the first 4 months with an interval of 2-4 weeks, and every 2 months thereafter. Blood was tested to look for signs of haemolytic anaemia (values determined were haemoglobin, haptoglobin, lactate dehydrogenase), thrombocytopenia and renal impairment. Furthermore, urine was collected to screen for proteinuria and haematuria.
Patients were advised to measure their blood pressure at home and in case of increased blood pressure, to contact their physician. All patients and their caregivers were strictly instructed to pay close attention to any signs of disease recurrence and were advised to contact their physician in case of any signs of infections, generalized malaise, fever, haematuria, oedema, oliguria, paleness or other signs indicating recurrence of aHUS. In case of aHUS recurrence, eculizumab was restarted immediately.
All kidney transplant recipients were treated according the protocol as described by Verhave et al. [21] . To prevent endothelial damage and thereby lowering the risk of aHUS recurrence, among others, patients were strictly monitored to prevent high calcineurin inhibitor levels, had aggressive blood pressure control, preferably with angiotensin-converting enzyme (ACE) inhibition, and were prescribed statins. In patients with aHUS in their native kidneys, we also adhered to tight blood pressure control. However, patients with well-controlled blood pressure and low cholesterol levels did not necessarily receive ACE inhibitors or statins.
Statistical analysis
Clinical variables were expressed for the total number of patients for whom data were available. Values were expressed as absolute numbers and percentages for categorical variables and as mean and SD or median and 25th-75th interquartile range (IQR) for continuous variables, as appropriate.
R E S U L T S

Patient characteristics
Between 2012 and 2016, a total of 20 patients, both adult (n ¼ 14) and paediatric (n ¼ 6), received eculizumab at the RUMC as treatment for aHUS ( Table 1) .
The median age at first presentation with aHUS was 24 (IQR 7-40) years and 13 (65%) patients were female. Five patients had a history of kidney transplantation. In 11 (55%) patients, a pathogenic mutation in complement genes or autoantibodies against CFH was found and 7 (35%) patients had a mutation of unknown significance (Table 1) . Of the 20 patients who received eculizumab treatment between 2012 and 2016, 4 patients (patients 1, 3, 16, 17) already received treatment for aHUS when eculizumab became available in The Netherlands in November 2012. Patients 3, 16 and 17 were PT dependent before they were switched to eculizumab and patient 1, previously PT dependent, continued eculizumab therapy after the clinical trial conducted by Alexion Pharmaceuticals ended (Table 1) . Since November 2012, 16 patients have presented with a new TMA episode, of which 7 patients initially received PT. However, due to either PT dependency (n ¼ 2) or PT resistance (n ¼ 5), eculizumab therapy was initiated. Nine patients received eculizumab without PT.
All paediatric patients reached remission with initiation of eculizumab. Of the 14 adult patients, all but 1 showed signs of aHUS remission after initiation of eculizumab. Patient 7, with a history of chronic renal failure of unknown origin for >10 years, did not show a renal response after eculizumab initiation. At presentation, this patient had high blood pressure, signs of TMA and further decline of renal function. Renal biopsy showed signs of mainly chronic TMA. Eculizumab was started immediately, but did not result in improvement of renal function, most likely due to the chronic condition. Therefore, eculizumab was stopped.
In the 19 responding patients, the median time until recovery of creatinine and thrombocytes was 39 (IQR 19-74) and 5 (IQR 2-6) days, respectively ( Table 2) .
Withdrawal of eculizumab therapy
Adults. Thirteen of the 14 adult patients have responded to eculizumab therapy. Therapy has been discontinued in all but one patient (Figure 1 ). Patient 6, who received a kidney transplant, has been treated with eculizumab for many years. Treatment with eculizumab at extended intervals resulted in low-grade TMA for which therapy was recently intensified. Of the 12 patients in whom therapy was discontinued, 3 experienced TMA recurrence at 2 weeks, 3 months and 12 months, respectively, after eculizumab withdrawal. Immediate initiation of eculizumab was effective and no clinical sequela such as more severe proteinuria or decline of kidney function were observed (Table 3 ). In patient 3, eculizumab was again withdrawn after an extended interval. The median duration of initial therapy was 3.8 (IQR 2.8-5.8) months. The median time of follow-up after the start of eculizumab therapy was 27.4 (IQR 7.8-42) months.
Children. In total, eculizumab therapy was given to six paediatric patients between 1 and 11 years of age. Until now, eculizumab treatment has been discontinued in four patients. In the remaining two patients the dosing interval was increased ( Figure 1 ). Patient 19 experienced a relapse at 12 months after eculizumab withdrawal, which was treated successfully for a period of 3 months with eculizumab (Table 3) . After reaching remission, eculizumab was again withdrawn. The paediatric patients had a median follow-up time after the start of eculizumab therapy of 31.3 (IQR 18.5-42.3) months.
Relapses
In total, five patients experienced a recurrence of aHUS (Table 3 ). Due to close monitoring and rapid reinitiation of eculizumab therapy, no chronic sequelae were detected in these patients (Table 3) . After clinical remission was reached, eculizumab was again withdrawn in two patients (Figure 1 ). The rate of relapses differed between the patient groups with various genetic variants: four of the eight patients with a CFH mutation and one of the four patients with a C3 mutation experienced a relapse. In patients with identified genetic variants in CFB (n ¼ 1), CFI (n ¼ 1), CFH-CHFR1 (n ¼ 3), in patients with autoantibodies against CFH (n ¼ 1) and in patients where no pathogenic mutation was detected (n ¼ 2), no aHUS recurrence was detected after therapy adjustment.
D I S C U S S I O N
Although eculizumab is recommended as lifelong therapy for patients with aHUS, this study shows that a short treatment period with eculizumab is feasible and, more importantly, safe and effective. Of the 20 patients, only 2 currently receive
Restrictive eculizumab regimen Restrictive eculizumab regimen eculizumab, according to SPC advice, at 2-week intervals. In total, eculizumab has been discontinued without aHUS recurrence in 13 patients, of which 5 are event free for >1 year. Our local restrictive treatment is effective, with 19 of the 20 patients showing TMA remission and improvement of kidney function. The duration of treatment in our centre deviates from the current international guideline and is based on the following principles: first, there is no proof that lifelong eculizumab therapy is needed and/or associated with improved survival.
Moreover, PT could be withdrawn in a substantial number of aHUS patients without disease recurrence. Additionally, most relapses occurred during the first year after disease onset. This risk decreased from >80% to $25% in almost all aHUS patients after the first year [3] . Second, treatment with eculizumab is not without risk, with the most prominent risk being meningococcal meningitis. Finally, the risk of aHUS recurrence depends on factors such as age of onset, genetic background of the patient, disease history (prior recurrence) and the presence of triggers, The identified genetic variant is described for each individual patient. The white bars indicate eculizumab discontinuation, the black bars indicate the time with eculizumab treatment as described in the SPC. In some patients the intervals between the eculizumab infusions were prolonged, as indicated by the dotted bars. aCFH, autoantibodies directed against complement factor H, C3, complement component C3; CFB, complement factor B; CFH, complement factor H; CFHR, complement factor H related protein; CFI, complement factor I. Values indicate TMA at the start of eculizumab. Serum creatinine value at recovery and days until recovery of creatinine are given. For a detailed description of the genetic variants per patient, see Table 1 . aCFH, autoantibodies directed against complement factor H; LDH, lactate dehydrogenase; NA, not applicable; SCr, serum creatinine. such as the use of calcineurin inhibitors after kidney transplantation or the presence of rejection [4, 8, [32] [33] [34] .
Based on these principles we have pursued eculizumab withdrawal in all aHUS patients. In adults with a primary aHUS episode in their native kidney, therapy withdrawal was considered after 3 months of therapy. In patients considered at high risk for relapse, such as adults who received kidney transplantation, or in patients with disease recurrence after eculizumab withdrawal, treatment was gradually extended. Extending the dose interval of eculizumab may seem irrational. However, we recently showed that the standard treatment regimen often leads to eculizumab serum levels that exceed the target level [18] .
In paediatric patients it can be difficult to differentiate between complaints possibly related to the use of eculizumab, such as infections due to their immunocompromised status, or possible side effects of the drug itself. The optimal treatment schedule of eculizumab in paediatric aHUS patients is yet to be established. Because children, especially young children, tend to experience more infections, which are an important trigger for aHUS recurrence, in most of our paediatric patients eculizumab treatment was first tapered before discontinuation [2, 33] .
Other studies have reported the successful discontinuation of eculizumab in patients with aHUS [12, 13, 16, 17, 19, 20] . The largest cohort was recently described by Fakhouri et al. [19] . This study included 108 patients who were treated with eculizumab for aHUS. Eculizumab was withdrawn in 38 patients (35%) after a median duration of treatment of 17.5 months. Follow-up after eculizumab withdrawal amounted to 22 months. During follow-up, 12 patients (32%) experienced a relapse. Re-treatment with eculizumab was successful. Although this and other studies provide evidence that eculizumab treatment can be stopped in some patients, there are some limitations. Most patients were treated with eculizumab for a long period of time. Most importantly, withdrawal of eculizumab was only attempted in a limited number of patients, which may have introduced selection bias.
Our study adds important new information. We have tried to withdraw eculizumab in all patients as early as 3 months after the start of therapy. Clearly, outcome in our patients was favourable, with $30% of patients experiencing a relapse that could be reversed with reintroduction of eculizumab. Obviously we cannot exclude that patients with a relapse after eculizumab withdrawal are at risk for more severe chronic kidney disease later in life. Therefore, it is important to be able to predict early relapses. Based on theoretical considerations, we have been reluctant to withdraw eculizumab in young children or in patients who had received a kidney transplant. In these patients we have extended the treatment interval to allow for evaluation of TMA signs in a period of less intensive complement blockade.
Literature data suggest that knowledge of the genetic defect may also aid in predicting relapses. Indeed, in the studies of Fakhouri et al. [19] and Ardissino et al. [13, 17] , most relapsing patients had a mutation in CFH. Likewise, four of five patients with a relapse in our study had a mutation in CFH. Still, in our view, predictive accuracy is too low: four patients in our cohort with a mutation in CFH did not experience a relapse after eculizumab discontinuation. Well-designed, prospective, multicentre, international studies may allow the identification of high-risk mutations that could guide individual therapy.
A restrictive treatment regimen is important in reducing possible long-term side effects and lowering the burden of lifelong eculizumab treatment. Furthermore, another important issue in our society is health care expenses. Eculizumab is known as one of world's most expensive drugs and treatment of one patient can cost up to half a million euros [11] . A restrictive treatment strategy will reduce costs considerably. Recently a cost-effectiveness analysis concerning treatment of aHUS in kidney transplant recipients was published [35] . van den Brand et al. [35] showed that induction therapy with eculizumab followed by lifelong treatment was inferior to eculizumab upon recurrence. This restrictive treatment strategy appeared to be cost effective. In addition, our data provide important information to allow cost-effectiveness analyses of treatment in patients with aHUS in the native kidney.
Our treatment strategy allowed early eculizumab withdrawal and thereby reduced drug costs in our patients. The total costs of treatment with eculizumab in these 20 patients were The disease course of this patients is described in Table 1 .
Restrictive eculizumab regimen $e7.3 million. This is a cost reduction of 62% when compared with the treatment regimen according to the EMA SPC, which would cost around e18.7 million. Obviously we have not performed a formal cost-effectiveness analysis. One important limitation of our observational study is that eculizumab withdrawal was not protocolized, but rather was based on clinical information and the assessment of the treating physician. Furthermore, it remains important to consider the importance of early recognition of symptoms indicating aHUS recurrence, which is sometimes difficult in young children. Future studies should help to identify a reliable predictor of disease recurrence. The most reliable markers may reflect complement activation in blood and on the cell surface, as previously suggested [36, 37] .
Prospective studies are needed to determine the optimal duration of treatment with eculizumab and evaluate prediction markers. Recently a national, prospective study called CUREiHUS (NTR5988) has started in The Netherlands. This study will include all aHUS patients and will monitor and evaluate the restrictive treatment regimen according to the new Dutch guideline. With the CUREiHUS study we hope to show that a restrictive treatment regimen is feasible. Moreover, we want to investigate the potential efficacy of this new treatment regimen from a societal perspective with the design of a costeffectiveness analysis.
In conclusion, discontinuation of eculizumab treatment in patients with aHUS is safe and effective, with close monitoring for signs of disease recurrence. This restrictive eculizumab regimen reduces costs considerably.
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